In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 105 for your search:
Drug:  paclitaxel albumin-stabilized nanoparticle formulation
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 65 and over
Sponsor: Other
Protocol IDs: GBG 52, 2008-003995-23, NCT01204437

2.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA031, NCT00540514

3.

Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: INST 0553C, NCI-2012-00946, NCT00659269

4.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00476, CDR0000617539, CALGB 40502, U10CA031946, P30CA014236, NCT00785291

5.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA046, NCT00844649

6.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA033, NCT00864253

7.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11-PIR-11, NCT01492101

8.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 69, 2011-004714-41, NCT01583426

9.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA015, NCT00073723

10.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-03111, ABI-CA015, NCT00077246

11.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA040, NCT00398086

12.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: DOXIL, NCT00442260

13.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000542904, UCD-185, UCDCC-185, UCD-200614714, NCT00470548

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-069, NCT00570674

15.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: CDR0000634258, SCCC-112008-019, ABX 236-HN08US, 112008-019, NCT00851877

16.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: ABXDDP20101224, NCT01735409

17.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA013-0, NCT00046514

18.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0309060, ABI-CA014, NCT00081042

19.

Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-04018, ABI-CA016, NCT00085605

20.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000423195, U10CA025224, N0531, 855-05, N0433, NCCTG-N0531, NCT00110084

21.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NSABP FB-AX-003, NCT00110695

22.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SCRI BRE 73, NCT00193206

23.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: I-04-012, NCT00251472

24.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCI 05-38, 2005-4550, NCT00254592

25.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: GOG-0127V, NCI-2009-00576, CDR0000463520, U10CA027469, NCT00309959
1     
New Search